Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...

Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are ...

the natural question becomes whether the stock is still a buy going forward. Let's see if the momentum can continue. While Ozempic has more brand recognition, Eli Lilly's Mounjaro and Zepbound ...

We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low ...

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

Eli Lilly continues to break new ground. Its famous weight loss medicine, Zepbound (tirzepatide), just became the first to earn approval from the Food and Drug Administration as a treatment for ...

The 8 best low-risk stocks to buy are listed in ascending order of ... a diabetes treatment, and Zepbound, a companion drug for chronic weight management. Both of these products have become ...